MedTrace Logo

Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

NCT03062319 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 321

Last updated 2024-12-27

No results posted yet for this study

Summary

The Purpose of this open-label randomized controlled multicenter trial is to evaluate the efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination therapy with antiplatelet drug, in ischemic stroke patients with non-valvular atrial fibrillation and atherothrombosis.

Conditions

Interventions

DRUG

Oral Anticoagulant

warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban

DRUG

Antiplatelet Drug

aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol

Sponsors & Collaborators

  • Network for Clinical Stroke Trials

    collaborator UNKNOWN

  • The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program

    collaborator UNKNOWN

  • National Hospital Organization Osaka National Hospital

    lead OTHER

Principal Investigators

  • Hiroshi Yamagami, MD · National Hospital Organization Osaka National Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-06
Primary Completion
2023-07-18
Completion
2023-07-18

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062319 on ClinicalTrials.gov